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Previous studies have reported inconsistent results on the effect of anthropometric and lifestyle factors on the risk of developing
glioma or meningioma tumours. A prospective cohort of 1.3 million middle-aged women was used to examine these relationships.
During 7.7 million women-years of follow-up, a total of 1563 women were diagnosed with a primary incident central nervous system
tumour: 646 tumours were classified as glioma and 390 as meningioma. Our results show that height is related to the incidence of all
central nervous system tumours with a risk of about 20% per 10cm increase in height (relative risk¼1.19, 95% CI¼1.10–1.30 per
10cm increase in height, Po0.001): the risks did not differ significantly between specified glioma and meningioma. Body mass index
(BMI) was also related to central nervous system tumour incidence, with a risk of about 20% per 10kgm
 2 increase in BMI (relative
risk¼1.17, 95% CI¼1.03–1.34 per 10kgm
 2 increase in BMI, P¼0.02). Smoking status, alcohol intake, socioeconomic level, parity,
age at first birth, and oral contraceptive use were not associated with the risk of glioma or meningioma tumours. In conclusion, for
women in the United Kingdom, the incidence of glioma or meningioma tumours increases with increasing height and increasing BMI.
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Primary brain and central nervous system cancers are relatively
rare and represent approximately 2% of all cancers diagnosed in
the United Kingdom. However, due to a poor prognosis, they are
responsible for 7% of the years of life lost from cancer before the
age of 70 years (Cancer Research UK, 2007). Very little is known
about the aetiology of central nervous system tumours, but
environmental factors are thought to play a role (McKinney, 2004;
Connelly and Malkin, 2007).
The two most common types of central nervous system tumour
are glioma and meningioma (Claus et al, 2005). Gliomas arise from
glial cells, are found predominantly in the brain and to a lesser
extent in the spinal cord or other parts of the central nervous
system, and represent more than 70% of all brain tumours (Ohgaki
and Kleihues, 2005). Gliomas are typically histologically malignant,
can be either slow or fast growing, and are more frequently
diagnosed in men than in women. Meningiomas arise from the
arachnoidal cells of the leptomeninges (the pia mater and
arachnoid mater of the meninges) (Sanson and Cornu, 2000), are
also more frequently found in the brain than elsewhere in the
central nervous system, and represent more than 20% of all brain
tumours (Longstreth et al, 1993). Meningiomas are typically
benign (490%) and slow growing. The risk of meningioma
increases with age (Sanson and Cornu, 2000), and they are more
frequently diagnosed in women (Sanson and Cornu, 2000;
Perry et al, 2007).
There are few well-established risk factors for glioma and
meningioma tumours among adults; while exposure to ionizing
radiation and rare inherited genetic conditions such as neuro-
fibromatosis (Martuza et al, 1988) are known to increase risk,
these factors explain only a small fraction of brain tumours
reported (McKinney, 2004). Several environmental factors
(including parity, smoking, mobile phone use, head trauma, and
occupational exposure) have been postulated as linked to tumour
development, mostly in case–control studies, but the evidence is
generally weak or inconsistent (Lambe et al, 1997; Inskip et al,
1998; Hu et al, 1999; Navas-Acie ´n et al, 2002; Hepworth et al, 2006;
Hardell et al, 2007). As central nervous system tumours are
relatively uncommon, studies of these tumours are limited by the
small number of cases, especially in cohort studies.
We report here results from analyses of the relationship between
anthropometric and lifestyle factors and the incidence of all
central nervous system tumours and of specified gliomas and
meningiomas in a large prospective cohort.
MATERIALS AND METHODS
Study population
During May 1996 to March 2001, 1.3 million middle-aged women
were recruited into the Million Women Study cohort, completing a
recruitment questionnaire about reproductive factors, sociodemo-
graphic factors, and other personal characteristics. Full details
of the study design and methods are described elsewhere
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http://www.million womenstudy.org. In brief, the Million Women
Study was designed as a prospective investigation into women’s
health, with a particular emphasis on breast cancer and exogenous
hormone use. All study participants have been flagged on the
National Health Service (NHS) central registers, so that tumour
registrations (benign and malignant) and deaths are routinely
notified to the study investigators. This information includes the
date of each such event and codes the tumour site and morphology
using the 10th revision of the International Classification of
Diseases (ICD-10) (World Health Organization, 1992) and the 3rd
Edition of Morphology and Neoplasms (Fritz et al, 2000).
Data collection
Incident central nervous system tumours were included from the
following sites: ICD-10 C70, C71, C72.0, C75.1–3, D32, D33,
D35.2–4, D42, D43, and D44.3–5. Incident cases of glioma,
morphology codes ICD-O 9380–9481, and meningioma, morpho-
logy codes ICD-O 9530–9539, were identified within these sites.
Statistical analysis
Women diagnosed before recruitment with any malignant tumour
(other than non-melanoma skin cancer (C44)) or a benign brain or
central nervous system tumour were excluded from the analysis. In
addition, we excluded women who reported having the inherited
disorder neurofibromatosis (Q85.0), a disorder of the nervous
system associated with a high risk of neurological tumours.
Eligible women contributed person years from the date of
recruitment until the date of registration with the tumour of
interest, date of death, or end of follow-up, whichever was the
earliest. In addition, women diagnosed with any cancer other than
the cancer of interest (except non-melanoma skin cancer) during
the follow-up period were censored at the date of diagnosis of that
cancer. The end of follow-up for cancer incidence was 31
December 2005 for all registries except Thames, North West
(Mersey), and Northern and Yorkshire regions, where follow-up
was to 31 December 2004, the West Midlands where it was 30 June
2005 and Scotland where it was 31 December 1999, as these regions
are complete only to these dates. Follow-up was complete for over
99% of the cohort population.
We considered all central nervous system tumours and each of
the specified tumour types (glioma and meningioma) as separate
end points in a Cox proportional hazards model with attained age
as the underlying time variable. We stratified analyses by broad
geographical region (10 regions corresponding to the areas
covered by the cancer registries), and we made adjustments for
height (o160, 160–164.9, X165cm), body mass index (BMI)
(o25, 25–29.9, X30kgm
 2), socioeconomic status based on
deprivation index (Townsend et al, 1988) (divided into thirds),
smoking status (never, past, current smoker), alcohol intake
(never, o1, X1U per day), strenuous exercise (o1, 1, X2 times
per week), age at first birth (o20, 20–24, X25 years old), parity
(full-term pregnancies) (0, 1–2, X3), and oral contraceptive use
(never, o5 years, X5 years), where appropriate. We assigned
women with missing values for any of the adjustment variables to a
separate category for that variable. All exposure data were self-
reported at recruitment.
Analyses adjusted only by age at recruitment and region were
conducted initially to estimate the relationship of each variable in
turn to the risk of all central nervous system tumours, glioma, and
meningioma. Subsequently, analyses were mutually adjusted for all
exposure variables to allow for possible confounding between
variables, as appropriate. The significance of categorical variables
was assessed using likelihood ratio tests, with the heterogeneity
P-values reported in the results. Tests for linear trend were
obtained by using the mid point values for each category and
treating this scored variable as continuous. These relative risks
were compared using a w
2 test for heterogeneity to see whether the
effect of each exposure variable varied between tumour types.
RESULTS
In total, 1249670 women aged between 50 and 65 years were
eligible for analysis, with an average age at recruitment of 55.9
years. A total of 1563 incident primary central nervous system
tumours were diagnosed after an average of 6.2 years follow-up
(7740300 woman-years). Of these, 646 tumours were classified as
glioma (98% as malignant) and 390 as meningioma (95% as
benign). Table 1 shows the baseline characteristics of the study
population and of women diagnosed with any central nervous
system tumour, with glioma, or with meningioma.
Table 2 shows relative risks for the incidence of all central
nervous system tumours and specified glioma and meningioma, by
height, BMI, strenuous exercise, socioeconomic level, smoking
status, alcohol intake, parity, age at first birth, and use of oral
contraceptives. Adjusted and unadjusted analyses gave very
similar results for all tumours and for each specified tumour type.
The relative risk for all central nervous system tumours increased
with increasing height, as did the relative risks of both glioma and
meningioma. The association of height and tumour risk was
significant for all central nervous system tumours (P for
heterogeneity o0.001) and modestly significant for glioma (P for
heterogeneity¼0.02). For meningioma, although the association
was not statistically significant, the relative risks were similar to
those for all central nervous system tumours and glioma (Table 2).
Figure 1 shows the relative risk for a 10cm increase in height and
tumour risk; relative risk for the incidence of all central nervous
system tumours increased by a factor of 1.19 per 10cm increase in
Table 1 Baseline characteristics of the study population according to the population at risk and tumour incidence
Characteristic Population at risk
All incident central
nervous system
tumours Incident glioma
Incident
meningioma
Number of women 1249670 1563 646 390
Mean age at entry (s.d.) 55.9 (4.5) 55.9 (4.5) 57.0 (4.5) 56.4 (4.7)
Upper third of socioeconomic group (n, %) 414816 (33.4) 527 (33.9) 214 (33.2) 134 (34.5)
Mean height, cm (s.d.) 162 (6.7) 163 (6.9) 163 (6.8) 162 (7.0)
Mean body mass index, kgm
 2 (s.d.) 26.2 (4.7) 26.4 (4.7) 26.2 (4.5) 26.8 (4.7)
Mean parity (s.d.) 2.1 (1.2) 2.2 (1.3) 2.2 (1.2) 2.2 (1.3)
Past use of oral contraceptive use (n, %) 742667 (60.1) 881 (57.0) 339 (53.1) 228 (59.4)
Strenuous physical activityXonce per week (n, %) 469568 (39.0) 539 (35.8) 223 (35.9) 120 (31.9)
Current smoker (n, %) 244363 (20.8) 256 (17.3) 107 (17.3) 70 (18.8)
Mean alcohol intake, gday
 1 (s.d.) 6.2 (7.6) 5.9 (7.3) 5.9 (7.4) 6.2 (7.2)
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tumours, the equivalent increase in risk was by factors of 1.24,
1.11, and 1.21, respectively, and there was no significant difference
between these relative risks (P for heterogeneity¼0.6).
Body mass index was also related to the incidence of all central
nervous system tumours, as well as to the incidence of
meningioma, and to a lesser extent, glioma (Table 2). For all
tumours and for meningioma, the association was statistically
significant (P for heterogeneity¼0.02, 0.03, respectively), with
obese women (BMIX30kgm
 2) having a relative risk of 1.21 (95%
CI¼1.04–1.39) and 1.40 (95% CI¼1.08–1.87), respectively, when
compared to women with a BMI o25kgm
 2. For glioma, obese
women had a non-significant relative risk of 1.07 (95% CI¼0.84–
1.34). Figure 1 shows that for all central nervous system tumours,
the relative risk per 10kgm
 2 increase in BMI increases by a factor
of 1.17; and by 1.07, 1.46, and 1.12 for the incidence of glioma,
meningioma, and other central nervous system tumours, respec-
tively. Again, no significant difference between these relative risks
for glioma, meningioma, and other central nervous system
tumours was observed (P for heterogeneity¼0.2).
Table 2 Relative risk of the incidence of all central nervous system tumours, incident glioma, and incident meningioma, by lifestyle factors
All central nervous system tumours (n¼1563) Glioma (n¼646) Meningioma (n¼390)
Variable of interest Population
a Cases RR
b RR
c (95% CI) Cases RR
b RR
c (95% CI) Cases RR
b RR
c (95% CI)
Height (cm)
o160 405831 435 1.00 1.00 177 1.00 1.00 115 1.00 1.00
160–164.9 367494 459 1.15 1.16 (1.02–1.33) 196 1.21 1.22 (0.99–1.49) 108 1.02 1.05 (0.81–1.37)
165+ 456174 639 1.28 1.31 (1.16–1.48) 262 1.30 1.31 (1.08–1.59) 157 1.19 1.25 (0.98–1.60)
Heterogeneity p o0.001 o0.001 0.02 0.02 0.3 0.2
Body mass index (kgm
 2)
o25 548846 632 1.00 1.00 259 1.00 1.00 154 1.00 1.00
25–29.9 422508 543 1.11 1.12 (1.00–1.26) 241 1.20 1.20 (1.01–1.44) 120 1.01 1.01 (0.79–1.29)
30+ 212871 289 1.20 1.21 (1.04–1.39) 106 1.06 1.07 (0.84–1.34) 84 1.42 1.40 (1.08–1.87)
Heterogeneity P 0.03 0.02 0.1 0.1 0.03 0.03
Strenuous exercise
o1 per week 733886 966 1.00 1.00 398 1.00 1.00 256 1.00 1.00
1 per week 216414 249 0.87 0.86 (0.75–0.99) 99 0.85 0.84 (0.67–1.05) 55 0.72 0.73 (0.55–0.98)
2+ per week 253154 290 0.86 0.86 (0.75–0.98) 124 0.91 0.91 (0.75–1.12) 65 0.72 0.73 (0.56–0.97)
Heterogeneity P 0.02 0.02 0.3 0.3 0.01 0.02
Socioeconomic level
Upper third 414816 527 1.00 1.00 214 1.00 1.00 134 1.00 1.00
Middle third 412630 530 0.99 0.99 (0.88–1.12) 216 1.00 1.01 (0.83–1.22) 125 0.92 0.91 (0.71–1.16)
Lower third 413041 498 0.98 0.98 (0.87–1.12) 214 1.01 1.04 (0.85–1.27) 129 1.00 0.96 (0.74–1.23)
Heterogeneity P 1.0 1.0 0.99 0.9 0.7 0.7
Smoking
Never 599949 819 1.00 1.00 322 1.00 1.00 203 1.00 1.00
Past 332775 407 0.92 0.91 (0.81–1.03) 189 1.08 1.09 (0.91–1.31) 99 0.89 0.86 (0.67–1.10)
Current 244363 256 0.84 0.85 (0.74–0.99) 107 0.89 0.91 (0.73–1.15) 70 0.91 0.88 (0.66–1.16)
Heterogeneity P 0.04 0.06 0.3 0.3 0.6 0.4
Alcohol intake (gday
 1)
Never 296765 376 0.98 0.98 (0.86–1.10) 151 0.90 0.90 (0.74–1.09) 92 1.02 0.98 (0.76–1.26)
o1 644775 834 1.00 1.00 357 1.00 1.00 198 1.00 1.00
1+ 298650 343 0.93 0.95 (0.84–1.08) 136 0.86 0.87 (0.71–1.06) 96 1.07 1.13 (0.88–1.44)
Heterogeneity P 0.5 0.7 0.3 0.3 0.9 0.6
Parity
0 134346 166 1.00 1.00 70 1.00 1.00 37 1.00 1.00
1–2 701479 846 0.97 1.01 (0.80–1.26) 355 0.97 0.92 (0.64–1.32) 215 1.09 1.18 (0.74–1.86)
3+ 411082 549 1.05 1.07 (0.86–1.33) 221 0.99 0.96 (0.68–1.35) 137 1.18 1.22 (0.78–1.89)
Heterogeneity P 0.4 0.5 0.96 0.9 0.6 0.7
Age at first birth (years)
o20 151798 184 1.00 1.00 68 1.00 1.00 50 1.00 1.00
20–24 522365 658 0.97 0.97 (0.82–1.14) 273 1.09 1.08 (0.82–1.41) 169 0.94 0.95 (0.69–1.31)
25+ 411369 532 0.99 0.99 (0.83–1.19) 227 1.14 1.13 (0.84–1.50) 124 0.88 0.89 (0.63–1.27)
Heterogeneity P 0.9 0.9 0.6 0.7 0.7 0.8
Oral contraception use duration
Never 493422 664 1.00 1.00 300 1.00 1.00 156 1.00 1.00
o5 years 298298 365 1.04 1.05 (0.92–1.20) 138 0.89 0.88 (0.72–1.09) 91 1.05 1.06 (0.81–1.38)
5+ years 412479 480 1.00 1.03 (0.91–1.16) 185 0.88 0.88 (0.72–1.06) 128 1.07 1.10 (0.86–1.40)
Heterogeneity P 0.8 0.8 0.3 0.3 0.9 0.8
Abbreviations: RR¼relative risk, 95% CI¼95% confidence interval.
aPopulation at risk at the start of the study.
bRelative risks stratified by region with attained age as the
underlying time variable.
cMultivariate relative risks mutually adjusting for all other variables in the table.
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nervous system tumours, glioma, and meningioma, with a
slightly lower risk in women who reported strenuous exercise
once per week or more often compared to women who exercised
less than once per week or never. Again, there was no significant
difference between the relative risks for glioma, meningioma, and
other central nervous system tumours, when comparing less
than weekly to at least weekly strenuous exercise (P for
heterogeneity¼0.2).
Socioeconomic level, daily alcohol intake, smoking status,
number of full-term pregnancies, age at first birth, and oral
contraceptive use were not associated with the incidence of all
central nervous system tumours, glioma, or meningioma.
The main analyses reported here focused on morphologically
specified glioma and meningioma tumours. Of the 527 ‘other
central nervous system tumours’ (as shown in Figure 1), 148 were
sited in the brain and 52 in the meninges, but all had non-specific
morphology codes. As all but 9 of the 646 specified gliomas were
sited in the brain (the remainder were in the spinal cord) and all
but 4 meningiomas were sited in the meninges (the remainder
were in the brain), it is reasonable to assume that the great
majority of morphologically unspecified tumours of the brain are
likely to be gliomas; and of the meninges, meningioma. Sensitivity
analyses showed that for a 10cm increase in height, the relative
risks were very similar for glioma (n¼646) and for all brain
tumours (n¼789) (relative risk¼1.24 (95% CI¼1.09–1.40) and
relative risk¼1.20 (95% CI¼1.07–1.34), respectively), and for
meningioma (n¼390) and for all meninges tumours (n¼438)
(relative risk¼1.11 (95% CI¼0.94–1.31) and relative risk¼1.17
(95% CI¼1.00–1.37), respectively). Similarly, for a 10kgm
 2
increase in BMI; the relative risks for glioma and for all brain
tumours were 1.07 (95% CI¼0.87–1.32) and 1.04 (95% CI¼0.86–
1.25), respectively, and the relative risks for meningioma and for
all meninges tumours were 1.46 (95% CI¼1.11–1.91) and 1.54
(95% CI¼1.20–1.99), respectively. The remaining central nervous
system tumours included 173 tumours of the cranial nerves (150
were of the 8th cranial nerve), 125 of the pituitary gland, 10 of the
spinal cord, 6 central nervous system tumours not otherwise
specified, and 13 other central nervous system tumours. The
number of tumours in these categories are at present too small to
allow reliable analysis.
DISCUSSION
Increasing height and BMI are associated with increasing incidence
of all central nervous system tumours, glioma, and meningioma in
this large cohort of middle-aged women.
Tumours of the brain and central nervous system are relatively
uncommon, and most of the evidence for potential risk factors
comes from case–control studies, as there are insufficient cases for
reliable estimations in most cohort studies. In addition, as
meningiomas are typically benign, their incidence is not reported
to cancer registries in some countries; therefore, these tumours are
not always included in some studies. Existing evidence on the role
of environmental risk factors and the incidence of glioma and
meningioma is thus limited.
For tumours of the central nervous system, there is limited and
inconsistent evidence about the effects of height (Helseth and
Tretli, 1989; Lee et al, 1997; Tulinius et al, 1997; Gunnell et al,
2001). Our results provide strong evidence that height is related to
the incidence of central nervous system tumours with a risk of
about 20% per 10cm increase in height, with no significant
differences between the effects for specified glioma and meningioma.
An association of this magnitude is consistent with that seen
between adult height and the incidence of several other common
cancers, including those of the breast and colon (Gunnell et al,
2004; World Cancer Research Fund/American Institute for Cancer
Research, 2007). The suggested mechanisms underlying these
associations include a simple link between height and cell number;
and the relation between rates of childhood growth and levels in
childhood and adulthood insulin-like growth factors, which may
influence cell proliferation and tumour growth (Gunnell et al,
2004).
Three of four previous cohort studies reported an increased risk
of the incidence of central nervous system tumours in relation to
obesity (Albanes and Taylor, 1990; Møller et al, 1994; Tulinius
et al, 1997), and one reported no association (Oh et al, 2005).
Evidence from case–control studies is also inconsistent (Bellur
et al, 1983; Helseth and Tretli, 1989; Schneider et al, 2005). This
present detailed analysis shows an increasing risk with increasing
BMI and central nervous system tumours (including specified
glioma and meningioma). Obesity may be related to cancer risk
through several possible mechanisms, including increased inflam-
matory response, decreased insulin sensitivity and, particularly in
women, through increases in circulating oestrogen levels (Reeves
et al, 2007; World Cancer Research Fund/American Institute for
Cancer Research, 2007). More evidence is needed on the
interrelated exposures of body size and both endogenous and
exogenous hormones in relation to brain cancer to explore
possible hormonal mechanisms (Claus et al, 2005).
We are not aware of any previous studies with evidence of an
association between physical activity and central nervous system
tumours. The main difference appeared to be between little or no
strenuous activity and some, with little suggestion of any
association with the amount of exercise. It is possible that the
Tumour type RRa per 10 cm increase
Height
Glioma (n=646) 1.24 (1.09–1.40)
Meningioma  (n=390) 1.11 (0.94–1.31)
Other CNS tumoursb  (n=527) 1.21 (1.05–1.39)
All CNS tumours  (n=1563) 1.19 (1.10–1.30)
0.5 1 2
RRa per 10 kg m–2 increase
Body mass index
1.07 (0.87–1.32)
1.46 (1.11–1.91)
1.12 (0.89–1.42)
1.17 (1.03–1.34)
0.5 1 2
a Relative risks were mutually adjusted for each other as well as socio-economic level, strenuous exercise, smoking status, daily alcohol intake, parity, age at first birth, and oral contraceptive use
b Includes type unspecified
RR: Relative risk, CI: Confidence interval, CNS: Central nervous system
Figure 1 Relative risks for a 10cm increase in height and 10kgm
 2 increase in body mass index.
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tumour symptoms such as headache may have prevented
strenuous exercise. Exclusion of the first 2 years of follow-up,
which should reduce this possible bias, did not materially affect the
relative risks in relation to strenuous exercise: for all central
nervous system tumours, the relative risks for strenuous exercise
once per week and two or more times per week compared with
little or no strenuous exercise were 0.86 (95% CI¼0.75–0.99) and
0.86 (95% CI¼0.75–0.98), respectively, and after exclusion of the
first 2 years of follow-up, the relative risks were 0.90 (95%
CI¼0.76–1.06) and 0.82 (95% CI¼0.70–0.96), respectively.
However, additional evidence is needed before the relevance of
these findings can be assessed.
The lack of association between smoking and the incidence of
glioma and meningioma is consistent with results from most
studies (Mills et al, 1989; Hurley, 1996; Zheng et al, 2001;
Schneider et al, 2005), but not all of them (Ryan et al, 1992; Efird
et al, 2004; Navarro Silvera et al, 2006a). Furthermore, smoking is
not classed as a risk factor for central nervous system tumours by
the International Agency for Research on Cancer in a recent
evaluation (International Agency for Research on Cancer, 2004).
The finding of no association between alcohol intake and the
incidence of glioma and meningioma is also supported by several
previous studies (Mills et al, 1989; Hurley, 1996; Hu et al, 1999;
Efird et al, 2004).
Parity and age at first birth have been associated with glioma
incidence in two studies (Lambe et al, 1997; Navarro Silvera et al,
2006b), but not with meningioma incidence (Lambe et al,1 9 9 7 ;
Jhawar et al, 2003); no association was evident in our study. In
addition, as in this study, previous studies have found no association
between oral contraceptive use and meningioma or glioma risk
(Jhawar et al, 2003; Custer et al, 2006; Wigertz et al, 2006).
The main strength of this study is that it is prospective;
therefore, recall bias was not a concern. Complete follow-up is
available for over 99% of the participants through the NHS central
registers with quality assurance of data. The very large study size
allows reliable estimation of relative risks for specific tumour types
defined by histology, even for less common tumours. The number
of cases in the Million Women Study cohort is greater than the
total in all previous cohort studies of glioma or meningioma and
similar risk factors.
The main limitation of this study is that exposure data are self-
reported. Previous studies investigating the accuracy of self-
reported vs measured height have shown that self-reported height
is a good indicator of measured height (Spencer et al, 2002;
Brunner, 2007). As with many large epidemiological studies, BMI
in our cohort was calculated based on self-reported height and
weight, thus is subject to both systematic and random errors. The
random component of this error is likely to be small (Whitlock
et al, 2001). The majority of the women in the study were moderate
drinkers (o1U per day), and so this study cannot examine the
effects of heavy drinking (X2U per day) as this group was
represented by only 5% of the population.
Our findings indicate that increasing height and increasing BMI
increase the incidence of all central nervous system tumours, and
of both glioma and meningioma tumours.
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